300 related articles for article (PubMed ID: 22307202)
1. High dose 1,25(OH)2D3 inhibits osteoblast mineralization in vitro.
Yamaguchi M; Weitzmann MN
Int J Mol Med; 2012 May; 29(5):934-8. PubMed ID: 22307202
[TBL] [Abstract][Full Text] [Related]
2. Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-kappaB.
Li Y; Li A; Strait K; Zhang H; Nanes MS; Weitzmann MN
J Bone Miner Res; 2007 May; 22(5):646-55. PubMed ID: 17266397
[TBL] [Abstract][Full Text] [Related]
3. Mineralization of three-dimensional osteoblast cultures is enhanced by the interaction of 1α,25-dihydroxyvitamin D3 and BMP2 via two specific vitamin D receptors.
Chen J; Dosier CR; Park JH; De S; Guldberg RE; Boyan BD; Schwartz Z
J Tissue Eng Regen Med; 2016 Jan; 10(1):40-51. PubMed ID: 23784946
[TBL] [Abstract][Full Text] [Related]
4. The bone anabolic carotenoid p-hydroxycinnamic acid promotes osteoblast mineralization and suppresses osteoclast differentiation by antagonizing NF-κB activation.
Yamaguchi M; Weitzmann MN
Int J Mol Med; 2012 Sep; 30(3):708-12. PubMed ID: 22751682
[TBL] [Abstract][Full Text] [Related]
5. Quercetin, a potent suppressor of NF-κB and Smad activation in osteoblasts.
Yamaguchi M; Weitzmann MN
Int J Mol Med; 2011 Oct; 28(4):521-5. PubMed ID: 21769418
[TBL] [Abstract][Full Text] [Related]
6. Evidence that both 1alpha,25-dihydroxyvitamin D3 and 24-hydroxylated D3 enhance human osteoblast differentiation and mineralization.
van Driel M; Koedam M; Buurman CJ; Roelse M; Weyts F; Chiba H; Uitterlinden AG; Pols HA; van Leeuwen JP
J Cell Biochem; 2006 Oct; 99(3):922-35. PubMed ID: 16741965
[TBL] [Abstract][Full Text] [Related]
7. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
[TBL] [Abstract][Full Text] [Related]
8. The vitamin D hormone and its nuclear receptor: molecular actions and disease states.
Haussler MR; Haussler CA; Jurutka PW; Thompson PD; Hsieh JC; Remus LS; Selznick SH; Whitfield GK
J Endocrinol; 1997 Sep; 154 Suppl():S57-73. PubMed ID: 9379138
[TBL] [Abstract][Full Text] [Related]
9. Regulation of osteocalcin production and bone resorption by 1,25-dihydroxyvitamin D3 in mouse long bones: interaction with the bone-derived growth factors TGF-beta and IGF-I.
Staal A; Geertsma-Kleinekoort WM; Van Den Bemd GJ; Buurman CJ; Birkenhäger JC; Pols HA; Van Leeuwen JP
J Bone Miner Res; 1998 Jan; 13(1):36-43. PubMed ID: 9443788
[TBL] [Abstract][Full Text] [Related]
10. 1,25-dihydroxyvitamin D3-mediated transforming growth factor-beta release is impaired in cultured osteoblasts from patients with multiple pituitary hormone deficiencies.
Sterck JG; Klein-Nulend J; Burger EH; Lips P
J Bone Miner Res; 1996 Mar; 11(3):367-76. PubMed ID: 8852947
[TBL] [Abstract][Full Text] [Related]
11. Stimulation by 1,25-dihydroxyvitamin D3 of in vitro mineralization induced by osteoblast-like MC3T3-E1 cells.
Matsumoto T; Igarashi C; Takeuchi Y; Harada S; Kikuchi T; Yamato H; Ogata E
Bone; 1991; 12(1):27-32. PubMed ID: 2054233
[TBL] [Abstract][Full Text] [Related]
12. Bone morphogenetic protein-2 restores mineralization in glucocorticoid-inhibited MC3T3-E1 osteoblast cultures.
Luppen CA; Smith E; Spevak L; Boskey AL; Frenkel B
J Bone Miner Res; 2003 Jul; 18(7):1186-97. PubMed ID: 12854828
[TBL] [Abstract][Full Text] [Related]
13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
14. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs.
Takasu H; Sugita A; Uchiyama Y; Katagiri N; Okazaki M; Ogata E; Ikeda K
J Clin Invest; 2006 Feb; 116(2):528-35. PubMed ID: 16424941
[TBL] [Abstract][Full Text] [Related]
15. COMP-Ang1, a chimeric form of Angiopoietin 1, enhances BMP2-induced osteoblast differentiation and bone formation.
Jeong BC; Kim HJ; Bae IH; Lee KN; Lee KY; Oh WM; Kim SH; Kang IC; Lee SE; Koh GY; Kim KK; Koh JT
Bone; 2010 Feb; 46(2):479-86. PubMed ID: 19782780
[TBL] [Abstract][Full Text] [Related]
16. Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells.
Inaba M; Terada M; Koyama H; Yoshida O; Ishimura E; Kawagishi T; Okuno Y; Nishizawa Y; Otani S; Morii H
J Bone Miner Res; 1995 Jul; 10(7):1050-6. PubMed ID: 7484280
[TBL] [Abstract][Full Text] [Related]
17. Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues.
Norman AW; Sergeev IN; Bishop JE; Okamura WH
Cancer Res; 1993 Sep; 53(17):3935-42. PubMed ID: 8395333
[TBL] [Abstract][Full Text] [Related]
18. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
19. Bone morphogenetic protein 2 enhances mouse osteoclast differentiation via increased levels of receptor activator of NF-κB ligand expression in osteoblasts.
Tachi K; Takami M; Zhao B; Mochizuki A; Yamada A; Miyamoto Y; Inoue T; Baba K; Kamijo R
Cell Tissue Res; 2010 Nov; 342(2):213-20. PubMed ID: 20941510
[TBL] [Abstract][Full Text] [Related]
20. Analysis of osteocalcin expression in transgenic mice reveals a species difference in vitamin D regulation of mouse and human osteocalcin genes.
Clemens TL; Tang H; Maeda S; Kesterson RA; Demayo F; Pike JW; Gundberg CM
J Bone Miner Res; 1997 Oct; 12(10):1570-6. PubMed ID: 9333117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
